Cancers (May 2021)

SEGHI Study: Defining the Best Surveillance Strategy in Hodgkin Lymphoma after First-Line Treatment

  • Mariana Bastos Oreiro,
  • Reyes Martín,
  • Pilar Gomez,
  • Nieves López Muñoz,
  • Antonia Rodriguez,
  • Marta Liébana,
  • Belén Navarro,
  • Blanca Sánchez-González,
  • Pilar Marí,
  • Jaime Pérez de Oteiza,
  • Antonio Gutiérrez,
  • Leyre Bento,
  • Eva Domingo Doménech,
  • María Jesús Vidal,
  • Raquel Del Campo,
  • Elena Pérez Ceballos,
  • María Infante,
  • Alicia Roldán,
  • Daniel García Belmonte,
  • Miriam Santero,
  • Anna Sureda,
  • Ramón García Sanz,
  • on behalf of the GELTAMO Group

DOI
https://doi.org/10.3390/cancers13102412
Journal volume & issue
Vol. 13, no. 10
p. 2412

Abstract

Read online

The optimal strategy for early surveillance after first complete response is unclear in Hodgkin lymphoma. Thus, we compared the various follow-up strategies in a multicenter study. All the included patients had a negative positron emission tomography/computed tomography at the end of induction therapy. From January 2007 to January 2018, we recruited 640 patients from 15 centers in Spain. Comparing the groups in which serial imaging were performed, the clinical/analytical follow-up group was exposed to significantly fewer imaging tests and less radiation. With a median follow-up of 127 months, progression-free survival at 60 months of the entire series was 88% and the overall survival was 97%. No significant differences in survival or progression-free survival were found among the various surveillance strategies. This study suggests that follow-up approaches with imaging in Hodgkin lymphoma provide no benefits for patient survival, and we believe that clinical/analytical surveillance for this group of patients could be the best course of action.

Keywords